News

Laurus Labs Q1 FY27: CDMO Revenue Up 67%, Net Profit Up 126% — The BIOSECURE Act Tailwind Is Now a Financial Statement

By Mustafa Shariff, Editor in Chief · July 28,2026 · 2 min read

Mustafa Shariff, Editor in Chief — Laurus Labs Q1 FY27: CDMO Revenue Up 67%, Net Profit Up 126% — The BIOSECURE Act Tailwind Is Now a Financial Statement

Summary

  • Laurus Labs Q1 FY27: CDMO Revenue Surges 67% to ₹870 Crore as Net Profit Jumps 126% — BIOSECURE Tailwind Hits the Financials
  • Laurus Labs reported Q1 FY27 record revenue of ₹2,026 crore (+29%), net profit ₹368 crore (+126%), EBITDA margin 31.8% (+700 bps) — driven by 67% surge in CDMO revenue to ₹870 crore as CDMO now represents 43% of total revenue.

"Laurus has delivered record quarterly revenue with expanded profitability and continued its portfolio transformation. This was driven by growing commercial deliveries within CDMO and continued strength in the Affordable Medicines portfolio. We strengthened our integrated offerings and niche capabilities that matter most to our clients. The structural shifts in global pharmaceutical supply chains are creating real opportunities for premium CDMO partners, and Laurus is well positioned to capture them."

Laurus Labs Limited reported its highest-ever quarterly revenue for the first quarter ended June 30, 2026 — ₹2,026 crore, up 29% year-on-year — alongside a 126% surge in net profit to ₹368 crore, driven by a 67% increase in CDMO revenue. The results, filed with BSE and NSE on July 24, 2026, represent the clearest financial evidence yet that the structural shift in global pharmaceutical supply chain strategy — driven significantly by the BIOSECURE Act's escalating implementation — is translating into real commercial momentum for India's CDMO sector.
The headline financials: consolidated revenue from operations reached ₹2,026.31 crore, compared with ₹1,569.57 crore in Q1 FY26. EBITDA reached ₹644 crore, up 66% year-on-year from ₹389 crore, with EBITDA margins expanding by 700 basis points to 31.8% from 24.8%. Gross margins improved 330 basis points to 62.7%. Profit before tax surged 114.7% to ₹481.36 crore. Net profit attributable to equity holders reached ₹367.60 crore, up 125.5% from ₹163.02 crore.
CDMO: The Engine Behind the Numbers
The CDMO segment's performance is the structural story within the quarterly results. Total CDMO revenue reached ₹870 crore for Q1 FY27 — up 67% year-on-year from the prior year quarter — with small molecules CDMO surging 69% to ₹835 crore, driven by commercial API supplies, late-stage clinical project ramp-ups, and rising demand across peptides, human health, animal health, and crop science applications. The CDMO Bio business contributed an additional ₹35 crore, up 21% year-on-year.
Critically, CDMO now represents 43% of Laurus Labs' total revenue — up from approximately 33% in the prior year quarter. This structural shift in revenue composition is what makes Laurus Labs' EBITDA margin expansion sustainable rather than cyclical: CDMO work generates structurally higher margins than commodity generic API production, and as CDMO's share of revenue increases, overall margin improvement follows mechanically from revenue mix shift.
Satyanarayana Chava, Founder and CEO of Laurus Labs, framed the commercial context: structural shifts in global pharmaceutical supply chains are creating real opportunities for premium CDMO partners — and Laurus is well-positioned to capture them. This is the language of a company that sees BIOSECURE Act-driven customer acquisition as a sustained commercial trend, not an opportunistic one-off.
The BIOSECURE Act Dimension
BHC Media has covered the BIOSECURE Act's escalating implementation timeline extensively throughout 2026: WuXi AppTec's Pentagon 1260H listing (June 8, covered June 23 edition), the Biotechnology Company of Concern designation expected by December 2026, and the five-year grace period on pre-listing contracts that means the main commercial wave reaches its peak intensity between 2028 and 2033. Laurus Labs' 125-plus active CDMO project pipeline, its greenfield expansion of ₹3,000-3,500 crore planned over FY27-FY29, and its strategic investments in peptide capabilities, ADC assets, and bio CDMO are all investments timed to be operational precisely when the BIOSECURE-driven customer qualification wave reaches peak intensity.
Affordable Medicines: Steady Contribution
Laurus's Affordable Medicines portfolio — generics finished dosage forms and active pharmaceutical ingredients — delivered steady growth alongside the CDMO surge. Total Affordable Medicines revenue reached ₹1,156 crore, up 10% year-on-year. Finished Dosage Form revenue grew 22% year-on-year to ₹502 crore, driven by new product launches in the US market. API revenue remained relatively flat at ₹654 crore. Anti-Retroviral combined revenue stood at ₹669 crore, up 3.4% year-on-year — maintaining Laurus's position as one of the world's largest ARV API suppliers.
BHC Perspective
At Bengaluru Health Community, Laurus Labs' Q1 FY27 results are a CDMO sector story of the highest commercial significance. EBITDA margins of 31.8% at 67% CDMO revenue growth confirm that India's CDMO sector is entering its premium phase — the phase where manufacturing quality, regulatory track record, and integrated service capability command pricing that reflects genuine value rather than cost-arbitrage. For BHC founders in CDMO services, pharmaceutical process technology, or API manufacturing — Laurus Labs' trajectory defines the financial outcome of the BIOSECURE opportunity, executed well.
Frequently Asked Questions
Q: What were Laurus Labs' Q1 FY27 results?
A: Consolidated revenue ₹2,026 crore (+29% YoY), highest-ever quarterly record. Net profit ₹368 crore (+126% YoY). EBITDA ₹644 crore (+66% YoY). EBITDA margin 31.8% (+700 bps). CDMO revenue ₹870 crore (+67% YoY), now 43% of total revenue.
Q: What drove the CDMO surge?
A: Small molecules CDMO revenue surged 69% to ₹835 crore, driven by commercial API supplies, late-stage clinical project ramp-ups, and rising demand across peptides, human health, animal health, and crop science. Active CDMO pipeline exceeds 125 projects.
Q: What is Laurus Labs' expansion plan?
A: ₹3,000-3,500 crore greenfield expansion over FY27-FY29, targeted at new commercial manufacturing assets in Visakhapatnam and integration of newly in-licensed ADC assets. Timed to be operational as BIOSECURE Act-driven customer qualification waves peak between 2028-2033.